BioNTech
Coverage of BioNTech in the Nexus archive.
- STAT+: BioNTech names Guido Oelkers its new CEO
BioNTech appointed Guido Oelkers as its new CEO, replacing Ugur Sahin. Oelkers, a biopharma industry veteran, will lead the company's shift toward oncology and aim for multiple approved medicines by 2030. Sahin and cofounder Özlem Türeci are leaving to launch a new biotech focused on mRNA medicines.
- STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
BioNTech and Pfizer presented bispecifics data at the ASCO annual meeting. FDA's Pazdur highlighted a positive outlook despite challenges. The article is part of STAT+'s coverage of the event.
- COVID pioneer BioNTech: The fall of Germany's pandemic hero
BioNTech, the German biotech company that gained prominence through COVID-19 vaccine development, is now facing challenges including declining vaccine demand, corporate restructuring, and the departure of its founders. The company is attempting to pivot toward cancer treatment trials to establish itself as a major biotech player beyond its initial pandemic success.